Related Experiment Video
Updated: Feb 25, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
The importance for immunoregulation for long-term cancer control
Alberto Fusi1,2, Angus Dalgleish1
1Infection & Immunity Research Center - St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.
Immune checkpoint blockade therapy offers breakthroughs for solid tumors like melanoma. Research focuses on improving patient response, minimizing side effects, and converting non-responders to responders for better cancer treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Immune checkpoint inhibitors (ICIs) represent a significant advancement in treating solid tumors, including melanoma.
- Combination therapy with ipilimumab and nivolumab demonstrates high efficacy in melanoma, yet approximately half of patients do not respond.
- Enhancing the therapeutic ratio and patient outcomes remains a critical challenge in cancer immunotherapy.
Purpose of the Study:
- To review recent findings in immune checkpoint blockade therapy for solid tumors.
- To address key research questions regarding maximizing treatment benefits and minimizing toxicity.
- To explore strategies for identifying likely responders and converting non-responders to immunotherapy.
Main Methods:
- Literature review of recent advancements in cancer immunotherapy.
- Analysis of current research trends and challenges in immune checkpoint blockade.
- Synthesis of findings related to patient selection and treatment optimization.
Main Results:
- Immune checkpoint blockade therapy has shown high response rates and durability in solid tumors.
- Combination therapy (ipilimumab/nivolumab) is effective in melanoma but not universally successful.
- Significant research efforts are directed towards improving patient stratification and overcoming resistance.
Conclusions:
- Further research is essential to optimize immune checkpoint blockade therapy for broader patient benefit.
- Developing strategies to identify responders and convert non-responders is crucial for advancing cancer treatment.
- Future directions include minimizing toxicity and maximizing efficacy in melanoma and other cancers.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cell-mediated Immune Responses
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

